Industry Focus

Rumors are swirling that Celgene may pay billions to buy Juno Therapeutics lock-stock-and-barrel. Do these rumors make sense? Also, how one tiny company is disrupting the $57 billion market for primary and specialty doctor visits. Is this healthcare's future?

Direct download: 20180117_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT